Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 15

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 15
---
 will not expire. We cannot predict when or whether any of the selling stockholders will exercise their pre-funded warrants. See “Prospectus Summary—Private Placement.”

The pre-funded warrants provide that a holder of pre-funded warrants does not have the right to exercise pre-funded warrants if such
holder, together with its affiliates, would beneficially own in excess of 4.99%, 9.99% or 19.99%, at the election of the holder, of the number of shares of our common stock outstanding immediately before or after giving effect to such exercise (the
“Beneficial Ownership Limitation”); provided, however, that each holder may increase the Beneficial Ownership Limitation by giving at least 61 days’ notice to the Company, but not in excess of 19.99%. Throughout this
prospectus, when we refer to the shares of common stock being registered on behalf of the selling stockholders, we are referring to the outstanding shares of our common stock and the shares issuable upon the exercise of outstanding pre-funded warrants without giving effect to the Beneficial Ownership Limitation.

The table below sets forth, to our
knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholders as of March 4, 2025. The information in the table below with respect to the selling stockholders has been obtained from the
respective selling stockholders. The selling stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See “Plan of Distribution” as may be supplemented and amended from time to time. We do
not know how long the selling stockholders will hold the shares before selling them, and except as set forth below under “Relationship with Selling Stockholders,” we currently have no agreements, arrangements or understandings with
the selling stockholders regarding the sale or other disposition of any of the shares.

The number of shares of common stock beneficially owned prior to
the offering for each selling stockholder includes (i) all shares of our common stock beneficially held by such selling stockholder as of March 4, 2025, (ii) the number of shares of our common stock that may be offered under this
prospectus, and (iii) the number and percentage of our common stock beneficially owned by the selling stockholders assuming all of the shares of our common stock registered hereunder are sold. The table below and footnotes assume that the
selling stockholders will sell all of the shares listed